All In Biotech

Drug Trial Radar · NCT02956629

Efficacy and Safety of Uprifosbuvir (MK-3682) + Ruzasvir (MK-8408) in Treating Hepatitis C Virus Infection Genotypes 1-6 (MK-3682-041)

A Phase 2, Open-Label Clinical Trial to Study the Efficacy and Safety of 12 Weeks of the Combination Regimen of MK-3682 + Ruzasvir in Subjects With Chronic Hepatitis C Virus (HCV) Genotype 1, 2, 3, 4, 5 or 6 Infection

Last checked: Nov 20, 2026Latest source record: Feb 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

282

Actual

Start

Nov 16, 2016

Primary completion

Dec 22, 2017

Study completion Mar 5, 2018

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Nov 7, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a nonrandomized, multi-site, open-label trial to evaluate a novel two-drug combination regimen (uprifosbuvir \[MK-3682\] 450 mg + ruzasvir \[RZR; MK-8408\] 180 mg once daily \[q.d.\] for 12 weeks) in male and female treatment-naïve (TN) or treatment-experienced (TE) participants with chronic hepatitis C virus (HCV) infection genotype (GT) GT1, GT2, GT3, GT4, GT5, or GT6 who have not previously received HCV direct-acting antiviral (DAA) therapy. Cirrhotic (C) and non-cirrhotic (NC) participants with and without human immunodeficiency virus (HIV) co-infection will be enrolled.

Conditions

  • Hepatitis C

Interventions

  • UprifosbuvirDrug

    Participants take 3 tablets each containing 150 mg uprifosbuvir q.d. by mouth.

  • RuzasvirDrug

    Participants take 3 capsules each containing 60 mg RZR q.d. by mouth.

  • RibavirinDrug

    RBV 200 mg capsules will be taken according to package instructions for a maximum of 16 weeks for any GT that meets virologic futility rules on uprifosbuvir + RZR alone.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Completing Study Therapy (SVR12)Time frame: 12 weeks after completing study therapy (Week 24)
  2. Percentage of Participants Experiencing an Adverse Event (AE)Time frame: Up to Week 14
  3. Percentage of Participants Experiencing an AE of Clinical Importance (ECI)Time frame: Up to Week 14
  4. Percentage of Participants Experiencing a Serious Adverse Event (SAE)Time frame: Up to Week 14
  5. Percentage of Participants Experiencing a Drug-related AETime frame: Up to Week 14
  6. Percentage of Participants Experiencing a Drug-related SAETime frame: Up to Week 14
  7. Percentage of Participants Discontinuing Study Therapy Due to an AETime frame: Up to Week 12

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.